https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Oncology
Celgene bags Inrebic FDA approval for myelofibrosis

Celgene bags Inrebic FDA approval for myelofibrosis

Inrebic FDA approval : Celgene’s subsidiary Impact Biomedicines, has bagged approval for its oral kinase inhibitor Inrebic (fedratinib) capsules from the US Food and Drug Administration (FDA) for the treatment of certain types of myelofibrosis, a rare bone marrow cancer. Fedratinib FDA approval is for the treatment of adult patients with intermediate-2 or high-risk primary […]

PAOLA 1 trial results : Lynparza, bevacizumab combo achieves PFS goal in phase 3 trial

PAOLA 1 trial results : Lynparza (olaparib), a cancer drug which was jointly developed by AstraZeneca and MSD, in combination with bevacizumab, met the primary endpoint of the phase 3 PAOLA 1 clinical trial in patients with advanced ovarian cancer. The PAOLA 1 primary endpoint is the statistically-significant and clinically-meaningful improvement shown by Lynparza plus […]

Continue reading …
Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS

Tagrisso FLAURA trial results : Pharma giant AstraZeneca said that the phase 3 FLAURA trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) has yielded positive overall survival (OS) results. The randomized, double-blinded, multicenter late-stage trial featured NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) […]

Continue reading …
ORIC Pharmaceuticals raises $55m to advance cancer resistance drugs

US oncology company ORIC Pharmaceuticals has raised $55 million through a Series D financing round to advance its pipeline of cancer resistance drugs, as per the latest pharma industry news. The financing brings the total capital raised by the San Fransisco-based ORIC Pharmaceuticals to more than $175 million. Leading the Series D financing round of the […]

Continue reading …
TRACON begins phase 1 TJD5 clinical trial in advanced solid tumors

TJD5 clinical trial : US biopharma company TRACON Pharmaceuticals has dosed the first patient in a US phase 1 clinical trial of I-Mab Biopharma’s CD73 antibody TJD5 (TJ004309) in patients with advanced solid tumors. TJD5 will be dosed in the early-stage trial as a single agent and also in combination with Roche’s PD-L1 antibody TECENTRIQ […]

Continue reading …
Daiichi Sankyo bags Turalio FDA approval for tenosynovial giant cell tumor

Turalio FDA approval : Daiichi Sankyo has secured approval for its CSF1R inhibitor Turalio (pexidartinib) from the US Food and Drug Administration (FDA) for the treatment of tenosynovial giant cell tumor (TGCT). The FDA approval of Turalio is for the treatment of adult patients having symptomatic tenosynovial giant cell tumor associated with severe morbidity or […]

Continue reading …
MONARCH 2 clinical trial results : Verzenio, fulvestrant combo improves overall survival in metastatic breast cancer

MONARCH 2 clinical trial results : Eli Lilly and Company (Lilly) said that Verzenio (abemaciclib) in combination with fulvestrant delivered a statistically significant improvement in overall survival in the phase 3 MONARCH 2 clinical trial held for a type of metastatic breast cancer. The US pharma giant said that the MONARCH 2 clinical trial results […]

Continue reading …
Sanofi, Regeneron secure Libtayo EMA approval for a type of skin cancer

Libtayo EMA approval : The European Commission has given conditional approval for Libtayo (cemiplimab) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), which is one of the most commonly diagnosed skin cancers. Libtayo, which is a fully-human monoclonal antibody targeting the immune checkpoint receptor programmed cell death […]

Continue reading …
Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics

Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as per the latest pharma acquisition news. AMAL Therapeutics, which was spun out from the University of Geneva in 2012, is focused on cancer immunotherapy and is engaged in advancing therapeutic […]

Continue reading …
Merck to acquire US biopharma company Peloton Therapeutics in $2.2bn deal

Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, according to pharma acquisition news. Based in Texas, Peloton Therapeutics is a clinical-stage company engaged in the development of small molecule therapeutics that target hypoxia-inducible factor-2α (HIF-2α) for the treatment […]

Continue reading …
Page 1 of 6123Next ›Last »